STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
Reported by STAT News · all stories from statnews.com
Editorial digest
Biotechnology enterprise Pathos completed a $237 million funding round, driving its market valuation to $3 billion. The capital increase underscores ongoing financial momentum behind computational platforms designed to accelerate pharmaceutical development.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/21/2026
STAT+: What’s the deal with Isomorphic Labs?
A new report examines the current standing and operations of drug discovery venture Isomorphic Labs.
- Trusted health newsroom10/14/2026
STAT+: The startup chasing ‘general biological intelligence’
A new company is pursuing advanced biological AI capabilities.
- Trusted health newsroom10/8/2026
STAT+: Why this startup is taking its AI to predict breast cancer risk directly to patients
A startup is offering AI-driven breast cancer risk assessment directly to individuals.
- Trusted health newsroom10/20/2026
Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary
A commentator reflects on audience fascination with Nathan Fielder's new documentary project about Elizabeth Holmes.
- Trusted health newsroom10/14/2026
How consumer tech company Whoop is building for Medicare patients
A consumer technology firm is developing products for older adults on Medicare.
- Trusted health newsroom9/8/2026
STAT+: Oura files to goes public, reported $1.2B in earnings
Oura has filed to go public after reporting $1.2 billion in earnings.